United Therapeutics Corporation
1110 Spring Street
Silver Spring
Maryland
20910
United States
Tel: 301-608-9292
Fax: 301-608-9291
Website: http://www.unither.com/
333 articles with United Therapeutics Corporation
-
United Therapeutics Releases its Annual Corporate Responsibility Report
9/10/2021
United Therapeutics Corporation (Nasdaq: UTHR) today announced the release of its second annual Corporate Responsibility Report with 2020 highlights
-
United Therapeutics Presents Tyvaso DPI™ BREEZE Clinical Data At The European Respiratory Society International Congress 2021
9/7/2021
United Therapeutics Corporation presented new clinical data from the BREEZE study evaluating Tyvaso DPI™ in patients with pulmonary arterial hypertension at the European Respiratory Society International Congress 2021.
-
United Therapeutics to Present Tyvaso DPI™ BREEZE Clinical Data at the European Respiratory Society International Congress 2021
8/24/2021
United Therapeutics Corporation announced it will present data from a clinical trial studying Tyvaso DPI™ in patients with pulmonary arterial hypertension at the European Respiratory Society International Congress 2021, which will be held virtually from September 5-8, 2021.
-
United Therapeutics Corporation Reports Second Quarter 2021 Financial Results
8/4/2021
United Therapeutics Corporation announced its financial results for the quarter ended June 30, 2021.
-
United Therapeutics Corporation To Present At The 2021 Wedbush PacGrow Healthcare Virtual Conference
8/3/2021
United Therapeutics Corporation announced that Martine Rothblatt, Ph.D., Chairperson and Chief Executive Officer of United Therapeutics, will provide an overview and update on the company's business during a fireside chat session at the 2021 Wedbush PacGrow Healthcare Virtual Conference.
-
United Therapeutics Corporation To Report Second Quarter 2021 Financial Results Before The Market Opens On Wednesday, August 4, 2021
7/28/2021
United Therapeutics Corporation announced that it will report its second quarter 2021 financial results before the market opens on Wednesday, August 4, 2021.
-
United Therapeutics Announces The Lancet Respiratory Medicine Publication Of Post-Hoc Analysis Of FVC Change From The Tyvaso® INCREASE Study
6/30/2021
United Therapeutics Corporation announced the publication in The Lancet Respiratory Medicine of a post-hoc analysis of forced vital capacity change in patients during the INCREASE study of Tyvaso® Inhalation Solution in patients with pulmonary hypertension associated with interstitial lung disease.
-
This program limits the prices drug manufacturers can charge for therapies sold to specific healthcare facilities, including public hospitals and community health centers.
-
United Therapeutics Announces FDA Acceptance of Tyvaso DPI™ New Drug Application For Priority Review
6/16/2021
United Therapeutics Corporation announced that the U.S. Food and Drug Administration accepted for priority review the New Drug Application for Tyvaso DPI™ for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.
-
MannKind and United Therapeutics Achieve a Major Milestone in the Development of Tyvaso DPI™ With New Drug Application Acceptance From the FDA
6/16/2021
MannKind Corporation and United Therapeutics Corporation reached a major milestone with the announcement that the U.S. Food and Drug Administration accepted for priority review of the New Drug Application for Tyvaso DPI™ for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.
-
Both MannKind and United Therapeutics entered into a global and exclusive licensing and collaboration agreement to develop and commercialize Tyvaso DPI.
-
United Therapeutics Pursues New Claims For Trade Secret Misappropriation Against Liquidia
6/7/2021
United Therapeutics Corporation (Nasdaq: UTHR) announced today that it is pursuing additional claims for trade secret misappropriation against Liquidia Technologies, Inc.
-
United claims Liquidia and a former employee misappropriated its trade secrets such as regulatory submissions and detailed financial forecasts for its inhaled treprostinil.
-
United Therapeutics Announces First Patient Enrolled In Phase 3 TETON Study Of Tyvaso In Patients With Idiopathic Pulmonary Fibrosis
6/3/2021
First pivotal study of Tyvaso® (treprostinil) Inhalation Solution outside pulmonary hypertension
-
United Therapeutics Corporation To Present At The Jefferies Virtual Healthcare Conference
5/25/2021
United Therapeutics Corporation announced that Mr. James Edgemond, Chief Financial Officer and Treasurer of United Therapeutics, will provide an overview and update on the company's business during a fireside chat session at the Jefferies Virtual Healthcare Conference.
-
United Therapeutics Corporation To Report First Quarter 2021 Financial Results Before The Market Opens On Wednesday, May 5, 2021
4/26/2021
United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its first quarter 2021 financial results before the market opens on Wednesday, May 5, 2021 . United Therapeutics will host a teleconference on Wednesday, May 5, 2021 , at 9:00 a.m. Eastern Time .
-
United Therapeutics Announces Submission of Tyvaso DPI™ New Drug Application to FDA
4/19/2021
NDA submission includes both pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease indications
-
Mannkind and United Therapeutics Reach a Milestone in the Development of Tyvaso DPI™ With New Drug Application Submitted to the FDA
4/19/2021
Following Afrezza®, Tyvaso DPI is the second compound formulated with Technosphere® technology to be reviewed by FDA
-
United Therapeutics Announces FDA Approval and Launch of Tyvaso® for the Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease
4/1/2021
First and only approved therapy in the United States for patients with PH-ILD, a serious, life-threatening disease with potentially more than 30,000 patients in need
-
The U.S. Food and Drug Administration approved two new treatments for multiple myeloma and pulmonary hypertension.